PubMed:33576494 / 93-298 JSONTXT

{"project":"LitCovid-sentences","denotations":[{"id":"T2","span":{"begin":0,"end":205},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Heterologous polyclonal antibodies might represent an alternative to the use of convalescent plasma or monoclonal antibodies (mAbs) in coronavirus disease (COVID-19) by targeting multiple antigen epitopes."}

{"project":"Covid19_manual_annotation_v2","denotations":[{"id":"T11","span":{"begin":24,"end":34},"obj":"Gene"},{"id":"T13","span":{"begin":114,"end":124},"obj":"Gene"},{"id":"T16","span":{"begin":0,"end":12},"obj":"Type"},{"id":"T17","span":{"begin":13,"end":23},"obj":"Type"},{"id":"T31","span":{"begin":103,"end":124},"obj":"Gene"},{"id":"T32","span":{"begin":126,"end":130},"obj":"Gene"},{"id":"T33","span":{"begin":93,"end":99},"obj":"Gene"},{"id":"T39","span":{"begin":73,"end":76},"obj":"Therapy"},{"id":"T40","span":{"begin":73,"end":76},"obj":"Therapy"},{"id":"T41","span":{"begin":73,"end":76},"obj":"Therapy"},{"id":"T57","span":{"begin":196,"end":204},"obj":"Biological"},{"id":"T6","span":{"begin":156,"end":164},"obj":"Disease"}],"relations":[{"id":"R11","pred":"using","subj":"T11","obj":"T39"},{"id":"R12","pred":"using","subj":"T33","obj":"T40"},{"id":"R13","pred":"using","subj":"T31","obj":"T41"},{"id":"R14","pred":"for","subj":"T39","obj":"T6"},{"id":"R15","pred":"for","subj":"T40","obj":"T6"},{"id":"R16","pred":"for","subj":"T41","obj":"T6"},{"id":"R6","pred":"abbreviation","subj":"T32","obj":"T31"},{"id":"R9","pred":"-","subj":"T33","obj":"T13"},{"id":"R7","pred":"of_a","subj":"T16","obj":"T11"},{"id":"R8","pred":"of_a","subj":"T17","obj":"T11"}],"attributes":[{"id":"A11","pred":"tao:has_database_id","subj":"T11","obj":"MESH:D000906"},{"id":"A64","pred":"tao:has_database_id","subj":"T33","obj":"MESH:D000906"},{"id":"A23","pred":"tao:has_database_id","subj":"T32","obj":"MESH:D000911"},{"id":"A6","pred":"tao:has_database_id","subj":"T6","obj":"MESH:C000657245"},{"id":"A22","pred":"tao:has_database_id","subj":"T31","obj":"MESH:D000911"},{"id":"A48","pred":"tao:has_database_id","subj":"T57","obj":"MESH:D000939"},{"id":"A65","pred":"tao:has_database_id","subj":"T13","obj":"MESH:D000906"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"BioProject","uri":"https://www.ncbi.nlm.nih.gov/bioproject/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"},{"prefix":"HP","uri":"https://hpo.jax.org/app/browse/term/HP:"},{"prefix":"BioSample","uri":"https://www.ncbi.nlm.nih.gov/biosample/"}],"text":"Heterologous polyclonal antibodies might represent an alternative to the use of convalescent plasma or monoclonal antibodies (mAbs) in coronavirus disease (COVID-19) by targeting multiple antigen epitopes."}

{"project":"Zoonoses","denotations":[{"id":"T11","span":{"begin":24,"end":34},"obj":"Gene"},{"id":"T13","span":{"begin":114,"end":124},"obj":"Gene"},{"id":"T16","span":{"begin":0,"end":12},"obj":"Type"},{"id":"T17","span":{"begin":13,"end":23},"obj":"Type"},{"id":"T31","span":{"begin":103,"end":124},"obj":"Gene"},{"id":"T32","span":{"begin":126,"end":130},"obj":"Gene"},{"id":"T33","span":{"begin":93,"end":99},"obj":"Gene"},{"id":"T39","span":{"begin":73,"end":76},"obj":"Therapy"},{"id":"T40","span":{"begin":73,"end":76},"obj":"Therapy"},{"id":"T41","span":{"begin":73,"end":76},"obj":"Therapy"},{"id":"T57","span":{"begin":196,"end":204},"obj":"Biological"},{"id":"T6","span":{"begin":156,"end":164},"obj":"Disease"}],"relations":[{"id":"R11","pred":"using","subj":"T11","obj":"T39"},{"id":"R12","pred":"using","subj":"T33","obj":"T40"},{"id":"R13","pred":"using","subj":"T31","obj":"T41"},{"id":"R14","pred":"for","subj":"T39","obj":"T6"},{"id":"R15","pred":"for","subj":"T40","obj":"T6"},{"id":"R16","pred":"for","subj":"T41","obj":"T6"},{"id":"R6","pred":"abbreviation","subj":"T32","obj":"T31"},{"id":"R7","pred":"of_a","subj":"T16","obj":"T11"},{"id":"R8","pred":"of_a","subj":"T17","obj":"T11"},{"id":"R9","pred":"-","subj":"T33","obj":"T13"}],"attributes":[{"id":"A48","pred":"tao:has_database_id","subj":"T57","obj":"MESH:D000939"},{"id":"A65","pred":"tao:has_database_id","subj":"T13","obj":"MESH:D000906"},{"id":"A6","pred":"tao:has_database_id","subj":"T6","obj":"MESH:D000086382"},{"id":"A11","pred":"tao:has_database_id","subj":"T11","obj":"MESH:D000906"},{"id":"A64","pred":"tao:has_database_id","subj":"T33","obj":"MESH:D000906"},{"id":"A23","pred":"tao:has_database_id","subj":"T32","obj":"MESH:D000911"},{"id":"A22","pred":"tao:has_database_id","subj":"T31","obj":"MESH:D000911"}],"text":"Heterologous polyclonal antibodies might represent an alternative to the use of convalescent plasma or monoclonal antibodies (mAbs) in coronavirus disease (COVID-19) by targeting multiple antigen epitopes."}

{"project":"Inflammaging","denotations":[{"id":"T2","span":{"begin":0,"end":205},"obj":"Sentence"},{"id":"T2","span":{"begin":0,"end":205},"obj":"Sentence"}],"text":"Heterologous polyclonal antibodies might represent an alternative to the use of convalescent plasma or monoclonal antibodies (mAbs) in coronavirus disease (COVID-19) by targeting multiple antigen epitopes."}

{"project":"Covid19_manual_annotation","denotations":[{"id":"T11","span":{"begin":24,"end":34},"obj":"Biological"},{"id":"T13","span":{"begin":114,"end":124},"obj":"Biological"},{"id":"T16","span":{"begin":0,"end":12},"obj":"Type"},{"id":"T17","span":{"begin":13,"end":23},"obj":"Type"},{"id":"T31","span":{"begin":103,"end":124},"obj":"Biological"},{"id":"T32","span":{"begin":126,"end":130},"obj":"Biological"},{"id":"T33","span":{"begin":93,"end":99},"obj":"Biological"},{"id":"T39","span":{"begin":73,"end":76},"obj":"Therapy"},{"id":"T40","span":{"begin":73,"end":76},"obj":"Therapy"},{"id":"T41","span":{"begin":73,"end":76},"obj":"Therapy"},{"id":"T57","span":{"begin":196,"end":204},"obj":"Biological"},{"id":"T6","span":{"begin":156,"end":164},"obj":"Disease"}],"relations":[{"id":"R15","pred":"for","subj":"T40","obj":"T6"},{"id":"R16","pred":"for","subj":"T41","obj":"T6"},{"id":"R11","pred":"using","subj":"T11","obj":"T39"},{"id":"R12","pred":"using","subj":"T33","obj":"T40"},{"id":"R13","pred":"using","subj":"T31","obj":"T41"},{"id":"R14","pred":"for","subj":"T39","obj":"T6"},{"id":"R6","pred":"abbreviation","subj":"T32","obj":"T31"},{"id":"R7","pred":"of_a","subj":"T16","obj":"T11"},{"id":"R8","pred":"of_a","subj":"T17","obj":"T11"},{"id":"R9","pred":"-","subj":"T33","obj":"T13"}],"attributes":[{"id":"A23","pred":"tao:has_database_id","subj":"T32","obj":"MESH:D000911"},{"id":"A11","pred":"tao:has_database_id","subj":"T11","obj":"MESH:D000906"},{"id":"A22","pred":"tao:has_database_id","subj":"T31","obj":"MESH:D000911"},{"id":"A6","pred":"tao:has_database_id","subj":"T6","obj":"MESH:C000657245"}],"text":"Heterologous polyclonal antibodies might represent an alternative to the use of convalescent plasma or monoclonal antibodies (mAbs) in coronavirus disease (COVID-19) by targeting multiple antigen epitopes."}